foxo4-dri cancer Development of a novel senolytic by precise disruption of FOXO4-p53 complex The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes Buy FOXO4 DRI (10mg) (Proxofim) 99% Purity USA Made Peptide FOXO4 DRI Peptide Nationwide Peptides By National Science Labs, LLC FOXO4 DRI 10mg vial Description RCpeptides Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry
Pay in 4 interest-free payments of $6.31 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7





